Research programme: idiopathic pulmonary fibrosis therapeutics - PureIMS
Latest Information Update: 25 Sep 2023
Price :
$50 *
At a glance
- Originator PureIMS
- Developer PureIMS; Undisclosed Company
- Class Antifibrotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Idiopathic pulmonary fibrosis
Most Recent Events
- 13 Jul 2023 Preclinical trials in Idiopathic pulmonary fibrosis in Netherlands (Inhalation) (PureIMS pipeline, July 2023)
- 31 Mar 2023 PureIMS has patents pending for Cyclops™ platform (PureIMS website, March 2023)